GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Goodwill-to-Asset

BNGO (Bionano Genomics) Goodwill-to-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Bionano Genomics's Goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil. Bionano Genomics's Total Assets for the quarter that ended in Sep. 2024 was $87.36 Mil. Therefore, Bionano Genomics's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 was 0.00.


Bionano Genomics Goodwill-to-Asset Historical Data

The historical data trend for Bionano Genomics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Goodwill-to-Asset Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial - 0.12 0.15 0.25 -

Bionano Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bionano Genomics's Goodwill-to-Asset

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics's Goodwill-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Goodwill-to-Asset falls into.



Bionano Genomics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Bionano Genomics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/214.404
=0.00

Bionano Genomics's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill to Asset (Q: Sep. 2024 )=Goodwill/Total Assets
=0/87.362
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionano Genomics  (NAS:BNGO) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Bionano Genomics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Executives
Gulsen Kama officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin director, officer: President and CEO 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon officer: General Counsel C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic director 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams officer: Chief Informatics Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy officer: Chief Business Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar officer: Chief Commercial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey officer: Chief Medical Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams officer: Chief Administrative Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011